Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-surgical lapatinib phase II study in primary breast cancer
ISRCTN71165034Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Sep 2006
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of lapatinib in breast cancer (2 cohorts), sponsored by Imperial College London. Primary endpoint: Tumor response by RECIST using ultrasound. Started Sep 2006; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN71165034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN71165034.